Literature DB >> 11086180

Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies.

I Shinozawa1, K Inokuchi, I Wakabayashi, K Dan.   

Abstract

Survivin is a newly discovered inhibitor of the apoptosis protein, IAP, expressed during development and in human cancers. The effector cell protease receptor-1 (EPR-1) gene is oriented in the opposite direction on the same DNA double strand. Thus, the Survivin and EPR-1 (Survivin/EPR-1) genes exist in a head-to-head configuration. It is not clear whether mutual expression of the Survivin/EPR-1 genes occurs in both normal cells and cancer cells. Here, we investigated the mutual expression of the Survivin/EPR-1 genes in 12 normal peripheral blood (PB) specimens, seven normal bone marrow (BM) specimens, five lymph node (LN) specimens, and seven leukemic cell lines, and 27 patients with malignant lymphoma (ML), four with acute lymphocytic leukemia (ALL), three with acute myelocytic leukemia (AML), and four with chronic myelocytic leukemia in blastic crisis (CML-BC). Using Northern blot analysis, small amounts of EPR-1 mRNA were detected in normal PB, normal BM and LN specimens, but no Survivin mRNA was detected. However, Survivin mRNA was detected in two of the 12 normal PB, six of the seven normal BM and one of the five LN specimens using reverse transcription and polymerase chain reaction (RT-PCR). Expression of both the Survivin and EPR-1 genes was detected in six of the seven cell line samples by Northern blot, and in all of them by RT-PCR. Mutual expression of the Survivin and EPR-1 genes was detected in three of the four CML-BC samples, 15 of the 27 ML samples, two of the four ALL samples, and all three AML samples using the RT-PCR method. No EPR-1 expression with or without Survivin expression was clearly detected in eight of the nine diffuse large B-cell lymphoma (DLB) specimens, two of the six follicular center lymphoma specimens, one of the four specimens of nodular sclerosis of Hodgkin's lymphoma, two of the four ALL specimens or one of the four CML-BC specimens. The data presented here show that disrupted expression of the Survivin/EPR-1 genes occurred in many kinds of hematologically malignant cells. This may be of biological importance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086180     DOI: 10.1016/s0145-2126(00)00065-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

Review 1.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.

Authors:  Amy B Hont; C Russell Cruz; Robert Ulrey; Barbara O'Brien; Maja Stanojevic; Anushree Datar; Shuroug Albihani; Devin Saunders; Ryo Hanajiri; Karuna Panchapakesan; Sam Darko; Payal Banerjee; Maria Fernanda Fortiz; Fahmida Hoq; Haili Lang; Yunfei Wang; Patrick J Hanley; Jeffrey S Dome; Catherine M Bollard; Holly J Meany
Journal:  J Clin Oncol       Date:  2019-07-29       Impact factor: 44.544

3.  Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.

Authors:  Shang-Mian Yie; Bie Luo; Nai-Yao Ye; Ke Xie; Shang-Rong Ye
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

4.  Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.

Authors:  Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

5.  CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.

Authors:  Elaine M Sloand; Loretta Pfannes; Gubin Chen; Simant Shah; Elena E Solomou; John Barrett; Neal S Young
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

6.  Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma.

Authors:  Xue-Quan Yao; Fu-Kun Liu; Jie-Shou Li; Xiao-Ping Qi; Bo Wu; Hong-Lin Yin; Heng-Hui Ma; Qun-Li Shi; Xiao-Jun Zhou
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

7.  Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells.

Authors:  Fuxue Chen; Yaming Xu; Youqun Luo; Da Zheng; Yichao Song; Kangkang Yu; Hong Li; Li Zhang; Weiwei Zhong; Yonghua Ji
Journal:  J Mol Neurosci       Date:  2010-03       Impact factor: 3.444

8.  Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.

Authors:  Zhiyu Liu; Zijun Y Xu-Monette; Xin Cao; Ganiraju C Manyam; Xiaoxiao Wang; Alexandar Tzankov; Yi Xia; Xin Li; Carlo Visco; Ruifang Sun; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Miguel A Piris; Jane N Winter; Dennis P O'Malley; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

9.  K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Authors:  B Douglas Smith; Yvette L Kasamon; Jeanne Kowalski; Christopher Gocke; Kathleen Murphy; Carole B Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; Lu Qin; Christina Chia; Barbara Biedrzycki; Thomas C Harding; Guang Haun Tu; Richard Jones; Kristen Hege; Hyam I Levitsky
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

Review 10.  Cellular and molecular themes in apoptosis.

Authors:  Faris Q Alenzi; Anthony N Warrens
Journal:  Wien Klin Wochenschr       Date:  2003-09-15       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.